Concord Biotech Strengthens Global Footprint: MFDS Korea Approves Dholka API Facility

Concord Biotech Limited, a leading Indian biopharma company, has successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS) of Korea at its Unit I API facility in Dholka, Gujarat. This approval further solidifies Concord's position in the global pharmaceutical market, adding to its impressive list of international certifications including USFDA, EUGMP, and PMDA Japan. The Dholka facility, established in 2000, spans 112,302 sq.m. and manufactures a wide range of APIs across therapeutic segments such as immunosuppressants, oncology, and antibacterials. This latest certification enhances Concord's ability to expand its presence in the Korean market and reinforces its commitment to maintaining high-quality manufacturing standards.

 

Sources: Concord Biotech Limited, BSE India, NSE India